GLP-1 receptor agonists have transformed the treatment of obesity and type 2 diabetes. Medications such as liraglutide, semaglutide, and tirzepatide are increasingly used as frontline therapies due to their remarkable efficacy for weight loss, glycemic control, and cardiovascular risk reduction. Still, more research is needed to better understand the full spectrum of benefits, side effects, and best practices – including which patients may respond better to GLP-1 drugs, and which patients may need additional support.
This is particularly true in integrative medicine where practitioners work diligently to create personalized protocols to meet each patient’s unique needs. And as GLP-1 drug use expands, providers are finding this individualized approach to be essential. That’s because research and clinical practice continue to underscore a common observation: two patients with seemingly similar metabolic profiles begin the same GLP-1 medication, and one experiences dramatic improvements while the other achieves only modest results at best.
Why? Genetics, diet, physical activity, sleep, medication adherence, and the degree of underlying metabolic dysfunction all play important roles. But emerging research suggests another possibility—that a patient’s inflammatory and fibrotic “metabolic terrain” may influence how well they respond to GLP-1 therapy.
One protein receiving increasing attention in this area is galectin-3 (Gal-3).
What Is Galectin-3?
Galectin-3 is a beta-galactoside-binding lectin expressed by activated macrophages, fibroblasts, and other cells and tissues throughout the body. It plays important roles in innate immunity, inflammation, tissue repair, fibrosis, and extracellular matrix remodeling.
Over the past decade, Gal-3 has become widely recognized as a culprit biomarker driving fibrosis and adverse outcomes in heart failure. Elevated Gal-3 has been associated in extensive research with obesity, insulin resistance, metabolic dysfunction, nonalcoholic fatty liver disease, and type 2 diabetes.
Rather than simply reflecting inflammation, Gal-3 identifies a broader state of chronic tissue remodeling and fibrosis that accompanies not just metabolic disease, but nearly every inflammatory condition impacting our health today—from cancer to Alzheimer’s, sepsis, and much more.
Go deeper into the science behind Galectin-3, including how targeting this rogue protein helps address a range of conditions, in our exclusive Galectin-3 Resource Center. You’ll also find links to webinars and podcasts such as “Demystifying Endotoxins: Identifying and Quenching the Fire Within” with Dr. Tom O’Bryan.
GLP-1 Therapy and Galectin-3
In addition to driving inflammatory conditions on its own, elevated Gal-3 is also shown to interfere with the efficacy of other drugs and treatments—including GLP-1 therapies.
A key study published in 2022 explored whether circulating Gal-3 levels might predict response to GLP-1 receptor agonist therapy. Investigators studied adults with obesity and either prediabetes or newly diagnosed type 2 diabetes who were randomized to receive either liraglutide plus lifestyle intervention support, or lifestyle interventions alone.1
Researchers demonstrated that patients with metabolic disease had significantly higher plasma Gal-3 concentrations than healthy controls, a finding that mirrored earlier data.
Importantly, the study also showed that baseline Gal-3 levels predicted improvement in beta-cell function during liraglutide treatment. Patients with lower baseline Gal-3 experienced greater improvements in β-cell function with GLP-1 therapies, whereas individuals with higher Gal-3 demonstrated a less favorable metabolic response.
The authors concluded that plasma Gal-3 may serve as a useful predictor of β-cell responsiveness to liraglutide, suggesting that the underlying inflammatory and fibrotic environment may influence therapeutic outcomes.
Does Galectin-3 Cause GLP-1 Resistance?
It is important to note that the authors of this study did not demonstrate that Gal-3 blocks GLP-1 receptors or directly interferes with GLP-1 signaling. Rather, elevated Gal-3 appears to identify patients with a more advanced inflammatory and fibrotic metabolic phenotype that may make it more difficult for GLP-1 therapies to work.
One possible explanation is that increased Gal-3 reflects a biological environment characterized by:
● Chronic low-grade inflammation
● Progressive tissue fibrosis
● Beta-cell dysfunction
● Reduced metabolic flexibility
● Greater insulin resistance
As researchers continue to investigate the relationships between Gal-3 and metabolic dysfunction, specific mechanisms by which Gal-3 activity may interact with GLP-1 therapies should become clearer.
“In addition to driving inflammatory conditions on its own, elevated Gal-3 is also shown to interfere with the efficacy of other drugs and treatments—including GLP-1 therapies.”
Toxins, GLP-1 Drugs and Metabolic Function
This metabolic-inflammatory lens also raises an important question for integrative practitioners who incorporate smart detoxification as a cornerstone of patient-centered care.
Environmental toxicants—including persistent organic pollutants (POPs), endocrine-disrupting chemicals, heavy metals, and other environmental triggers—have long been associated with chronic inflammation, oxidative stress, fibrosis, and metabolic dysfunction including diabetes and obesity. In fact, researchers sometimes refer to these pollutants as obesogens or diabetogens because of their pathogenic role in these complex conditions.
A 2019 in-vitro study using human enteroendocrine cells demonstrated that mixtures of human-relevant persistent organic pollutants altered GLP-1 secretion. Importantly, the investigators found no evidence that these pollutants directly impaired GLP-1 receptor activation. Instead, their findings suggest that environmental chemicals may influence incretin biology upstream by altering hormone secretion rather than receptor function.2
More concerning however, is the increasing body of data showing that rapid weight loss, regardless of the approach, may expose patients to the problem of autointoxication. This happens when toxins are released from their storage sites in the body too quickly, without proper binding and detoxification support, and end up redistributing to sensitive areas such as the brain. Toxin redistribution is increasingly suspected to be a factor in the progression of more serious conditions and concerns, including premature mortality, as shown in large-scale data.3
Modified Citrus Pectin, Gal-3, & Metabolic Health
One of the best-studied Gal-3 inhibitors is modified citrus pectin (MCP), a low-molecular-weight polysaccharide derived from citrus peel that binds to the carbohydrate recognition domain of Gal-3, interfering with its biological activity. Numerous published studies have demonstrated that MCP can reduce Gal-3-mediated inflammation and fibrosis in multiple organ systems. A handful of studies also show MCP helps to improve outcomes of other therapies, by way of Gal-3 inhibition and the downstream effects in tissues and organs. In addition, published clinical data shows that MCP helps to bind and remove several toxic heavy metals—including lead, arsenic, and cadmium—without depleting essential minerals, making it unique among natural compounds studied for detoxification. MCP has been recommended for over three decades as a clinical adjunct for key areas of health, and as research continues, is increasingly used to support metabolic health and related functions.4,5
Clinical Applications and Future Research
As research and clinical interest expands, Galectin-3 is proving to be an important piece of the personalized medicine puzzle. Clinicians increasingly rely on this active, culprit biomarker to help better individualize treatment strategies and monitor their patients’ progress. Modified citrus pectin, which has demonstrated Gal-3 inhibitory activity and metal-binding properties in preclinical and early clinical studies, represents a promising avenue for future research in this area.
As of today. GLP-1 receptor agonists remain among the most effective therapies available for obesity and type 2 diabetes, yet patient response varies considerably. Emerging evidence suggests that baseline Galectin-3 may help predict improvements in β-cell function during GLP-1 receptor agonist therapy, offering a practical view into how a patient’s inflammatory and fibrotic biology may influence treatment response. This evolving area of research reminds us that successful integrative care extends well beyond prescribing medication. Understanding—and improving—the biological terrain in which these therapies work may ultimately help us deliver more personalized, effective care for our patients.
→ For more information about this article, visit ecoNugenics Professional.
References
- Simeone PG, et al. Effects of liraglutide vs lifestyle changes on soluble ST2 and galectin-3 in obese subjects with prediabetes or type 2 diabetes. Cardiovasc Diabetol. 2022;21:63. https://pmc.ncbi.nlm.nih.gov/articles/PMC8917620/
- Shannon M, et al. A Human Relevant Defined Mixture of Persistent Organic Pollutants (POPs) Affects In Vitro Secretion of Glucagon-Like Peptide 1 (GLP-1), but Does Not Affect Translocation of Its Receptor. Toxicol Sci. 2019 Dec 1;172(2):359-367. doi: 10.1093/toxsci/kfz192. PMID: 31432086.
- McEvoy ME, Kandil K. GLP-1 agonists and persistent organic pollutants (POPs): lipophilic toxin mobilization during rapid fat loss. Naturopathic Doctor News & Review. Published April 2026. Accessed August 3, 2026. https://ndnr.com/glp-1-agonists-and-persistent-organic-pollutants-pops-lipophilic-toxin-mobilization-during-rapid-fat-loss/
- Eliaz I, Raz A. Pleiotropic Effects of Modified Citrus Pectin. Nutrients. 2019 Nov 1;11(11):2619. doi: 10.3390/nu11112619. PMID: 31683865; PMCID: PMC6893732.
- Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytother Res. 2006 Oct;20(10):859-64. doi: 10.1002/ptr.1953. PMID: 16835878.
